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Intravitreal injection of a therapeutic substance is the most common procedure performed in ophthalmology. It has a low
incidence of serious complications but is associated with a small chance of endophthalmitis. Although the rate of endophthalmitis
is between 0.019% and 0.09%, the associated visual morbidity is often devastating. Procedural changes have evolved over the years
to improve patient comfort and reduce injection-related injury and infection. Despite the availability of published evidence, there
remains considerable variations and lack of consensus in practical clinical settings. In addition, emerging literature concerning the
use of speculums, the use of prophylactic topical antibiotics, and the setting of injections continues to impact the ophthal-
mologist’s injection practice. +is article provides an up to date assessment of various aspects of the procedure such as the setting,
ventilation, type of anaesthetic, and control of sterility during the procedure; including discussions on performing bilateral eye
same-day injections and the use of antibiotics.
1. Introduction
Intravitreal injection (IVI) is the most commonly performed
ophthalmic procedure and is likely the most commonly
performed surgical procedure in medicine. +e use of the
intravitreal route of administration of anti-VEGF agents to
treat diabetic macular oedema, exudative age-related mac-
ular degeneration, and retinal vasoocclusive disease has
proven to be a legitimate medical breakthrough, and their
use has grown dramatically [1]. +e most feared compli-
cation of intravitreal injection is endophthalmitis, which is
associated with a poor visual prognosis even with prompt
diagnosis and treatment with intravitreal antibiotics or
vitrectomy, and visual loss is common [2]. +e incidence of
endophthalmitis varies amongst studies. Various multi-
centre randomized controlled trials of anti-VEGF admin-
istration have reported incidences between 0.019% and
0.09%; however, these figures are in prospective trial con-
ditions [3, 4]. Nonetheless, a systematic review of 20 large
retrospective case series supported these figures, with an
estimated endophthalmitis rate of 0.028% (1/3,544 in-
jections) [5]. As a reference range for this review, the range
between 0.019% and 0.09%, is used.
Anti-VEGF injections are used in a growing population of
patients, and as treatment is maintained in existing patients,
the number of treatment events continues to grow. +is is
advantageous to the patient, but more treatment events yield
more chances for complications andmore focus is required in
planning to reduce the outcome of endophthalmitis. Despite
the current availability of evidence, there are considerable
variations and a lack of consensus and inconsistencies in
clinical practice. Given the importance of the topic, the sci-
entific literature relating to various aspects of the procedure is
frequently updated, with recent controversies particularly
surrounding the prophylactic use of topical antibiotics, same-
day bilateral injections, and the setting of injections. +is
paper summarises the latest developments, reviews estab-
lished evidence-based aspects of endophthalmitis prophylaxis
in intravitreal injections, presents selected general scientific
data of direct application to the ophthalmologist when
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optimising their injection technique, and highlights areas
where further clinical research is required.
2. Topical Irrigation/Antisepsis
2.1. Povidone Iodine. Ophthalmic or “half strength”
povidone-iodine is routinely used in ophthalmic surgery due
to its broad spectrum antimicrobial activity, low incidence of
microorganism resistance, cost-effectiveness, and wide
availability [6]. As endophthalmitis is hypothesized to occur
due to inoculation or ingress of microorganisms into the
globe during injection, sterilizing of the ocular surface is of
paramount importance and the central evidence-based
recommendation of any injection protocol.
+e omission of topical antiseptic is associated with
significantly higher rates of endophthalmitis. In a study
reported by DRCR.net, 3123 eyes received 28,786 intra-
vitreous injections, usually with povidone-iodine prepara-
tion. However, a total of 13 injections in 2 participants were
administered without antiseptic and both participants de-
veloped endophthalmitis in 1 eye each. +is was 15% risk of
endophthalmitis per injection. 100% of the at risk subjects
develop endophthalmitis during the short duration of the
treatments [7].
To date, the technique, concentration, and contact time
of povidone-iodine still remains a matter of study. For
example, a technique of a 10ml flush of 5% povidone-iodine
through the conjunctival fornix provided greater reduction
of bacteria than a 2-3 drop application of 5% povidone-
iodine [8] and a 30 sec exposure time to 5% povidone-iodine
is associated with a significantly greater reduction in bac-
terial load than 15 secs [9].
While it is considered a necessity to use povidone-iodine
or alternative antiseptic as an aseptic measure, repeated
exposure of ocular surface does seem to lead to increasing
reports of dry eye symptoms. +erefore, there is a need for
health professionals to be aware of these changes and to
manage these symptoms and risks [10].
2.2. Chlorhexidine. Aqueous chlorhexidine 0.1% is reported
to be a good alternative to povidone-iodine for antisepsis in
patients with significant postprocedure pain for intravitreal
injection. In a pain survey scale of 0–10, patient discomfort is
reported to be lower (3/10) using chlorhexidine compared
with 8/10 using 5% povidone-iodine [11]. In addition, the
efficacy of chlorhexidine is similar to povidone-iodine when
investigating ocular bacterial count after antisepsis [12, 13].
In a multicentre retrospective case series using aqueous
chlorhexidine, the endophthalmitis rate was 0.0074%, which
compares favourably with povidone-iodine [13].
Although chlorhexidine compares well with povidone-
iodine preparation and is widely used, there are reports of
resistance in methicillin-resistant Staphylococcus aureus and
fungi. On the other hand, there are no similar reports of
resistance with povidone-iodine use [14].
2.3. Saline/BalancedSalt Solution. Although saline irrigation
is ineffective in reducing bacteria count and may even
increase bacterial count coming from the fornices, post-
injection pain is often reported by patients as a result of the
irritant effect of povidone-iodine or other antiseptics
[12, 15]. It shows saline irrigation postinjection does de-
crease discomfort. In an attempt to decrease patient dis-
comfort and to minimize epithelial toxicity, practitioners do
irrigate ocular surfaces after intravitreal injection regardless
of whether chlorhexidine or povidone-iodine is used as the
antiseptic agent. Unfortunately, there is no evidence on the
safety or otherwise of this practice.
Topical antiseptic is therefore critical to use prior to
intravitreal injection, providing relative sterility in the im-
mediate injection environment. +e most widely preferred
antiseptic is 5% povidone-iodine with contact time of at least
30 secs. Despite adequate topical anaesthesia, povidone-
iodine can cause significant postoperative ocular surface
irritation; however, no data on the safety of subsequent
irrigation of the ocular surface with saline are available.
3. Setting of Procedure: Office Setting versus
Operating Theatre
+e modern intravitreal injection procedure is a modified
posterior chamber paracentesis manoeuvre of traditional
vitreoretinal surgery, and therefore many centres initiated
early anti-VEGF treatments in the operating room envi-
ronment. More recently, surveys assessing the settings for
delivering intravitreal injections have shown a preference for
an office or clean room environment, including a study from
the UK which reported 83% of intravitreal injections were
performed in a dedicated clean roomwith sterile preparation
[16] and in Canada, where a majority of intravitreal in-
jections were performed in the office setting [17]. Whether
the setting of administration of intravitreal therapy in-
fluences the incidence of endophthalmitis has been widely
debated. Certainly, an operative setting can be associated
with exceeding small incidences of endophthalmitis: in
a 2017 retrospective multicentre study of 134,701 injections
across Europe, an endophthalmitis rate of 0.0074% was
achieved in operating theatres [18]. Tabendeh et al. con-
ducted a retrospective review of a total of 11,710 intravenous
injections, where 8,647 intravitreal injections were done in
an office-based setting and 3,063 were performed in the
operating room. 5 endophthalmitis cases (0.043%–0.035% in
office-based procedures and 0.065% in operating room
procedures) were with no significant difference in the rate of
endophthalmitis between the groups [19]. +ese results are
further supported by a meta-analysis which showed no
safety benefits in the administration of intravitreal injection
in either the outpatient clinic, surgery, or at another location
[20]. +ere are, however, other reports that the operating
theatre is safer than the office-based setting. Abell et al.
reported that operating room procedures were associated
with a 13-fold decreased risk of endophthalmitis compared
office-based procedures. +e usual quoted confounding bias
in Abell’s study was patients who had injections in theatre
were privately insured, while those who have their injections
in office were not, [21] however, it must be commented that
other retrospective studies may well have admitted more
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complicated or higher risk patients for operating room
procedures, creating a reverse bias more likely to favour the
office-based setting.
+e figures also highlight the principle difficulty in
performing studies and interpreting the results of all papers
concerning postinjection endophthalmitis: namely, due to
its very low incidence, even very large treatment cohorts
yield very small numbers of affected individuals. Prospective
trials of sufficient power to assess interventions for effec-
tiveness must often number in the tens of thousands to
achieve statistically significant differences between groups,
and depending on the cost or invasiveness of the in-
tervention being assessed, even statistically significant dif-
ferences may not be clinically relevant.
Given the evidence shows it is safe to give intravitreal
therapy either in office setting or operating room, it seems
more cost effective, convenient, and efficient to perform
intravitreal injections in an office setting. Nonetheless, this is
surprising as first principles would seem to indicate that the
negative pressure environment of the operating theatre
should be safer, andmany surgeons understandably prefer to
treat their patients in the operating theatre environment for
this reason.
4. Ventilation
Part of the reason for the hypothesis that the operating
theatre is a safer setting for intervitreal injection is the
theoretical importance of air-borne particles in causing
infection. +e efficacy of ultraclean air in significantly re-
ducing infection rates was first demonstrated in orthopaedic
implant surgery [22].
One new study trialled the use of a mobile ultraclean
unidirectional airflow screen (UDF) to reduce airborne
particles in simulated intravitreal injections. In the study, the
UDFmobile screen reduced the mean particle concentration
(particles >0.3 microns) over the stimulated ocular surface
by at least a factor of 436 (p< 0.05) and on the instrument
table by a factor of at least 100 (p< 0.05), clinically trans-
lating into significantly reduced air contamination. It ap-
pears the mobile UDF screen may provide a theoretically
safer procedural environment for intravitreal injections in
the office setting, but there remains no evidence that this will
translate into lower endophthalmitis rates [23].
Indeed the relationship between air changes per hour
and incidence of postoperative endophthalmitis generally
has not been established. +e ESCRS conducted a study of
postphacoemulsification endophthalmitis comparing mini-
mal airflow, 20 air changes per hour, and ultraclean air
systems using either horizontal or vertical laminar airflow
systems with no clear results [24]. It is proposed a similar
future study could be carried out for postintravitreal in-
jection endophthalmitis.
5. Respiratory Droplet Reduction
Face masks minimize aerosolisation of orophrayngeal
droplets and are used throughout surgical specialties to
reduce infection. +e most commonly cultured bacteria in
injection-related endophthalmitis are Staphylococcus species
followed by Streptococcus, [25] and since Streptococcus are
normal commensal organisms of the upper respiratory and
oral cavities but usually not the conjunctival membranes, it
has been suggested that dispersion of oral flora from either
the treating physician or the patient themselves is one
mechanism of endophthalmitis [26].
In a meta-analysis of endophthalmitis postintravitreal
injection, McCannal reported 31% were due to Streptococcus
species, a figure 3 times higher than that in other surgical
procedures [27]. A retrospective study to assess the effect of
a 2 year “no talking” period during the injection procedure
reported the stringent policy was associated with a decreased
rate of postinjection endophthalmitis, and a reduction of
Streptococcus-associated endophthalmitis from 0.015% to
0.002% [28]. In another study, the use of a face mask and
avoidance of talking significantly decreased the dispersion of
respiratory flora during intravitreal injections. However, this
microbiological study of a simulated injection environment
also reported that even without a face mask or silence, use of
povidone-iodine was associated with the least bacterial
growth, demonstrating once again the paramount impor-
tance of conjunctival antisepsis in the procedure [29]. +ese
findings have been widely adopted: in the UK, for example,
82% of 125 ophthalmologists used sterile adhesive eye drapes
to isolate patients’ nasopharyngeal area and periocular re-
gion [30].
Based on these findings, it would appear prudent for all
staff members and patients who are present in the room to
wear amask during procedure setup and performance and to
be instructed to minimize talking. Although maintaining
silence is preferred, these findings must be weighed against
the clinical importance of patient instructions and re-
assurance whilst performing the procedure.
6. Use of Gloves
+e literature would indicate there is a surprisingly wide
variation in clinical practise regarding the use of gloves,
sterile or nonsterile, during intravitreal injection. In a survey
of 717 US-based retinal specialists, 51% reported using 1 pair
of gloves, 46% reported no gloves, and 3% used 2 pairs of
gloves during intravitreal injections [31], whilst in Israel,
75% of 72 retinal specialists reported wearing sterile gloves
for intravitreal injections [32].
Consistent with modern-day medical practise of invasive
procedures, it is the authors’ opinion that the use of sterile
gloves is generally recommended. However, the scientific
basis of this perception is challenged by a study conducted by
Bhavsar et al. in which the study protocol required only
nonsterile gloves and the rate of endophthalmitis was low. It
was argued that the primary requirement for endoph-
thalmitis prophylaxis was a procedural needle which
remained sterile and a prepared eye surface is prepared [4].
Similar findings are reported in another study where the rate
of endophthalmitis was 0.057% per injection in a total of
14,895 injections administered without the use of sterile
gloves [33].
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+ere is therefore insufficient data supporting the role of
sterile gloves in reducing risk of postintravitreal injection
endophthalmitis.+erefore, a practitioner may argue against
the necessity of sterile gloves in this procedure with some
degree of evidence-based backing; however, in many ju-
risdictions their use is likely to be mandatory.
7. Hand Hygiene and Antisepsis
+e practise of hand hygiene is a fundamental element of
medical practice, and general hand hygiene practice is to
perform hand antisepsis regardless of the intention to use
gloves. Although there are no studies directly linking type of
hand antisepsis with endophthalmitis, the ophthalmologist
should be aware of the efficacy of different antisepsis so-
lutions, particularly when planning office-based in-
frastructure for an intraocular procedure. +ere are 2 main
types of antisepsis solutions: aqueous scrubs and alcohol
rubs. +e major aqueous scrubs can be further divided into
povidone-iodine, chlorhexidine, and triclosan [34].
In a randomized control trial, studying the effects of
conventional chlorhexidine, povidone-iodine, and alcohol
hand rub, chlorhexidine and the alcohol rub provided better
antiseptic effectiveness than povidone–iodine, [35] and in
general, alcohol rubs have superior antimicrobial efficacy
than aqueous scrubs [36, 37] with a rapid reduction of
microbial count and bacterial regrowth to baseline taking
more than 6 hours [38].
Nonetheless, a Cochrane review investigating all hand
antisepsis approaches concluded there was no firm evidence
that one type of hand antisepsis was better than another,
although alcohol rubs with additional antiseptic ingredients
may reduce colony-forming units, and all the evidence of
hand antisepsis available were of low or very low quality [34].
In real-life clinical practise, it is observed that alcohol hand
rub may be a more favourable choice for surgical staff due to
its antimicrobial efficacy, speed, and comfort.
8. Eyelid Retraction and Speculums
Eyelids, eyelid glands, and eyelashes are sources of infection in
intraocular surgery regardless of antiseptic solution used, and
surgical instruments must avoid touching them where pos-
sible. An eye speculum is one way to avoid contamination of
the procedural needle, and previous studies suggest it lowers
endophthalmitis rates by preventing causative pathogens
contaminating the needle or the injection field [39]. In the
United States, 92% of retinal specialists who participated in
a survey stated they routinely used an eyelid speculum [31]. In
the VISION trial of pegaptanib, no speculum was used with
some patients, and the endophthalmitis rate was high at 0.18%
per injection, but much higher amongst those patients in
whom the speculum was not used [40].
Alternative techniques in isolating eyelids and eyelashes
may also be acceptable in achieving the aim of the lid
speculum. In a retrospective case series of 78,009 intravitreal
injections, a lid-splinting eyelid retraction technique was used
and an endophthalmitis rate of 0.015% was reported, similar
to that of a lid speculum [41]. +e finding is interesting
because usage of an eyelid speculum is often associated with
discomfort: a recent prospective study reported a majority of
patients prefer bimanual eyelid retraction in comparison to
a metal lid speculum as it was associated with less pain and
discomfort [42].
Nonetheless, most practitioners have limited experience
with alternative methods of eyelid retraction and studies
must be conducted in other centres to compare the safety
benefit and consistency of alternative eyelid retraction
techniques prior to any discontinuation of lid speculum use
for intravitreal injections.
9. Prophylactic Antibiotics
Topical prophylactic antibiotics have wide applications in
surgery, and their use was initially extended to intravitreal
injections, as it was assumed that they would reduce the risk
of postinjection endophthalmitis in the same way that
topical fourth generation fluoroquinolones and intracameral
antibiotics reduced endophthalmitis risk in phacoemulsifi-
cation surgery.
+ere is currently no trial that shows prophylactic topical
antibiotics reduce the risk of postinjection endophthalmitis;
however, the mechanism of this lack of efficacy remains
unknown. In a retrospective case-control study of 117,171
injections, prophylactic antibiotic use was not associated
with a change in the endophthalmitis rate (0.049% with
antibiotics; 0.032% without) [43]. A more surprising finding
is that of two meta-analyses which conclude prophylactic
antibiotics actually increase the risk of endophthalmitis. In
the first, data from 276,774 injections were analysed: 39.45%
with prophylactic antibiotics and 60.55% without. +e
analysis of this data showed the risk of endophthalmitis was
actually 1.70 times higher (p � 0.02) with antibiotics than
without. In the second, a pooled analysis of 639,391 anti-
VEGF intravitreal injections, the incidence of endoph-
thalmitis with topical antibiotic prophylaxis was three times
with antibiotic use (0.09% versus 0.03%) [44].
+emechanism has been thought to be due to increasing
the ratio of antibiotic-resistant surface bacteria and the
overall pattern of resistance of periocular flora [20, 45] or the
repeated use of fluoroquinolones having a detrimental effect
on ocular surface health. Fluoroquinolone drops certainly
result in increased resistance rates: in one study the con-
junctival flora showed an 87.5% antibiotic resistance rate
after 4 days of treatment [46].
Whilst this theory certainly explains a trend towards
more challenging cases of endophthalmitis, the mechanism
of a greater chance of bacterial ingress into the globe during
the procedure remains unclear to the authors. If routine
antibiotic use is prospectively shown to be associated with an
increased endophthalmitis rate (as opposed to severity),
alternative explanations could include the use of any
postoperative drop or irrigation leading to ocular surface
disturbance or increased tear film movement over the op-
erative site, or increased handling of the eye by the patient
leading to a higher chance or postoperative wound leak,
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thereby increasing the chance of postoperative ingress of
infective organisms.
Unsurprisingly, recent evidence indicates an abandon-
ment of prophylactic topical antibiotic use in the practice of
some practitioners, but this has not been based on the results
of prospective data. Given equivalent trials and their success
in phacoemulsification surgery, such a trial would not be
unreasonable, and currently the use of prophylactic topical
antibiotics is still the usual practice for a significant per-
centage of practitioners. Regardless, it seems uncontroversial
that, given the frequency of injections, the practitioner must
assume that preoperative and postoperative courses of an-
tibiotics will cause substantial ocular surface antibiotic
resistance.
10. Anaesthesia
Patients often experience pain during intravitreal injections
and the use of local anaesthetics aim to minimize discomfort
and avoid pain-induced rapid or uncontrolledmovements of
the eye [47]. Any protocol designed to minimize endoph-
thalmitis must both sterilise the surgical field but also
maintain patient comfort and compliance whilst minimising
patient movement, and both the effectiveness and sterility of
the anaesthesic method are obviously central to this effort.
Currently, there is lack of consensus of which anaesthetic
techniques are the best option for either maintaining sterility
or patient compliance for intravitreal injections. A recent
systematic review evaluating the effectiveness of different
local anaesthetic techniques for intravitreal injections in-
cluded local eye drop anaesthetics (tetracaine, proparacaine,
and cocaine), lidocaine gel, lidocaine pledget, subcon-
junctival anaesthesia, and peribulbar block. It concluded
patient discomfort was mild regardless of technique; how-
ever, it stated subconjunctival injection may be an option for
highly sensitive patients [48], and this is supported by
a survey of patients’ preference of topical anaesthesia, which
revealed 88% of the patients preferred subconjunctival an-
aesthesia over 12% of topical anaesthesia for ongoing
intravitreal injections [49].
Andrade et al. reported a subconjunctival injection of 2%
lidocaine was more effective for intravitreal injections
compared to lidocaine gel or proparacaine drops [50]. Li-
docaine itself has mild antiseptic properties, and Tustin et al.
found no cases of culture positive endophthalmitis in
a retrospective series of 6,583 injections using subcon-
junctival lidocaine versus 8 cases in a series of 8,189 cases
using other methods (p � 0.03), implying the significant
difference could be due to anaesthetic’s aseptic nature. +e
actual mechanism could, of course, be multifactorial and is
likely to include some combination of the extended contact
time of povidone-iodine, some unknown diluting or sepa-
rating effect of the conjunctival bleb, the mild antiseptic
effect of the agent itself, and improved intraoperative and
postoperative patient compliance.
It should be noted that topical lidocaine gel has also been
reported as a barrier to topical antiseptics reaching the ocular
surface in in vitro models [51]. When applied prior to
povidone-iodine, lidocaine gel application has been associated
with an increased rate of postinjection endophthalmitis [52],
but when povidone-iodine was applied first, subsequent li-
docaine gel did not increase the rate of endophthalmitis in
a retrospective series of 8802 injections [53]. It would
therefore appear prudent to apply copious antiseptic agent to
the surgical site as early as possible in the procedure and
certainly before gel or subconjunctival anaesthesia is
administered.
11. Bilateral Intravitreal Injection
In many ophthalmologists’ practices, same-day bilateral
intraocular interventions have historically been studiously
avoided due to the risks of bilateral blindness from an
unknown systematic cause on the day. Nonetheless, the
incidence of bilateral diabetic macular oedema and cho-
roidal neovascularisation has meant that it has become
increasingly common for patients to request bilateral same-
day treatment, and many clinicians are beginning to offer
this service. Taking an independent risk of endophthalmitis
at the upper end of the range, at 0.09% or 1/1,111, the risk of
bilateral blindness of two completely independent pro-
cedures should be 1 in 1.2 million injections. Unfortunately,
bilateral intravitreal injections are not independent pro-
cedures: even if separate packs, drapes, and lot numbers are
used, the room, proceduralists, and patient are the same.+e
1/1,111 risk is based on a unilateral injection and an already
uncomfortable patient undergoing and recovering from
a second procedure will have binocular visual impact and
bilateral visual discomfort and is therefore unlikely to have
such low risks. An untrained attendant, a ventilation
problem on the day of the procedure, a problem in the
patient’s home, or an iatrogenic infection caused by an
incipient URTI in any participant all make the independent
probability calculation essentially worthless to the prac-
tioner’s decision of whether to offer the service.
In a study conducted in a veteran hospital, 660 patients
received bilateral same-day injection. Both eyes were prepared
and injected sequentially without reuse of instruments or
medications. No serious ocular complications including bi-
lateral infectious or noninfectious endophthalmitis or retinal
detachment were noted when standard aseptic protocol was
observed [54]. In another study, Ruao et al. reported no
culture-proven endophthalmitis after bilateral injection and
a lower rate of acute intraocular inflammation relative to
a unilateral treatment group (0.062% versus 0.152%) [55]. A
lower infection rate in bilateral injections was also reported in
a study by Ruao [55], where severe intraocular inflammation
rates of 0.274% in 8172 unilateral injections compared
favourably to 0.062% of 1612 bilateral injections. All these
studies suggest that bilateral same-day injections are relatively
safe clinical decision to make or recommend. However, the
studies do have some caveats, especially the high rates of
intraocular inflammation in unilaterally treated patients in
Ruao’s study and the low power of the other studies compared
with the numerous single-eye studies. In addition, in the
absence of an unknown physiological mechanism, the ap-
parently lower level of inflammation/infection in the
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bilaterally treated patients can only reasonably be interpreted
as either patient selection bias towards healthier patients for
the bilateral option or increased care on the part of the
procedural team when performing the bilateral procedures.
+is complicates interpretation of these studies substantially.
+e clinical outcome of a bilateral case of endoph-
thalmitis is perhaps easier for the clinician to interpret.
Tabatabelli [56] reported 2 cases of bilateral endophthalmitis
in patients with diabetic macular oedema, with final vision of
light perception in one patient and 20/400 in the other. A
second report (unpublished data) presented at the 2016
Australian and New Zealand Society of Retinal Specialists
Meeting reported a patient who presented with unilateral
low grade vitreous cells 2 days following bilateral intravitreal
injections and underwent a sterile vitreous tap and injection
of intravitreal antibiotics. 2 days later, the same patient
presented with frank endophthalmitis in the other eye,
subsequently losing the vision but fortunately retaining the
vision in the first.+ere has also been an interesting report of
bilateral reactivation of herpes simplex keratitis following
bilateral intravitreal injections [57].
Nonetheless, although same-day bilateral treatment has
not been studied in randomized or large controlled trials, the
practice is thought to have become more common as it is
generally well tolerated and preferred by patients and ad-
ministrators [58]. Despite retrospective results to the con-
trary, there is no credible evidence that bilateral injections
reduce the risk of injection associated endophthalmitis. If
undertaken, it is imperative that intravitreal treatment of
each eye be considered as a separate, sterile procedure,
conducted with new lot numbers and without reusing in-
struments or medications to avoid increasing the risk of
bilateral endophthalmitis.
12. Conclusion
+is review aimed at examining factors that can be used to
reduce or prevent post-intravitreal injection-related
endophthalmitis. +e authors believe there is evidence to
recommend (in order of strength of evidence): povidone-
iodine antisepsis (aqueous chlorhexidine where this is not
possible), eyelid retraction with speculum, prevention of
droplet spread via masks, adhesive drapes and reduced
talking, and subconjunctival anaesthetic with lidocaine base
agent. In addition to this, good sterile procedure and
compliance with local policies including hand hygiene, use
of gloves, staff training, and ensuring the chosen operative
setting is optimised to the surgeon’s satisfaction, whether
a theatre or clean room is chosen. Bilateral same-day in-
jections may be safe and can be implemented in clinical
practice; however, the clinical risks of one patient compli-
cation may outweigh the convenience benefits in many
practitioners’ minds. +e omission of prophylactic topical
antibiotics seems justified by the existing literature; however,
prospective trials are lacking. Mobile airflow screens, al-
ternative eyelid retraction methods, and the question of
whether postprocedure saline irrigation is beneficial or
detrimental are all important developments to be explored in
the future.
It should be stressed that in all of these cases, evidence
quality is low and the difficulties discussed in studying
a complication that occurs only once in every 1 to 4
thousand interventions means a clinicians’ surgical skills,
general training, clinical perspective, and experience con-
tinues to have a substantial role in preventing adverse events
in this, the most commonly performed surgical procedure in
ophthalmology.
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